$PHVS

Pharvaris N.V.

Pharvaris develops oral therapies for rare diseases with significant unmet need, initially focusing on bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency. Its main product candidate, deucrictibant, is a small-molecule bradykinin B2 receptor antagonist being studied in two formulations: an immediate-release capsule for on-demand treatment of attacks and an extended-release tablet for once-daily prevention. Pharvaris also runs clinical studies of deucrictibant for both treatment and prevention of acquired angioedema attacks. Pharvaris is based in Leiden, the Netherlands. It is developing its product candidates through clinical trials and intends to retain their economic and commercial ownership. If approved, it expects to commercialize both formulations in the United States and is evaluating independent commercialization and partnerships in other geographies.

2
0
1

No SEC Form 4 filings for $PHVS in the last 30 days.

See all $PHVS insider activity →
High

Pharvaris (PHVS) Reports 83% Lower HAE Attack Rate Versus Placebo

Pharvaris (PHVS) reported that its drug deucrictibant XR reduced HAE attack rates by 83% versus placebo in a Phase 3 trial. The trial met all primary and secondary endpoints, with 45% of participants attack-free over 24 weeks. No serious adverse events were reported.

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.

PHVS sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 3 news stories mentioning PHVS (Pharvaris N.V.). Coverage has skewed bullish: 2 bullish, 0 neutral, and 1 bearish.

Recent PHVS coverage spans financial news, earnings and technology.

What's driving PHVS

AlphAI scores every news story that mentions PHVS with an AI model for sentiment and relevance, and aggregates insider trades from Pharvaris N.V.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $PHVS

Score

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.

Here are Friday's biggest analyst calls: Nvidia, SpaceX, CoreWeave, Deckers, Unusual Machines & more

Analysts made several calls on Friday. Roth initiated Natera and Guardant Health with buy ratings, targeting $475 and growth respectively. PhillipCapital upgraded SpaceX to buy with a $250 price target. Seaport reiterated Nvidia as sell due to competitive pressures. Barclays initiated Rush Street Interactive at overweight. Piper Sandler downgraded Deckers to underweight. Jefferies upgraded MSC Industrial to buy. Citizens initiated Microbot Medical at market outperform.

Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet

Pharvaris (PHVS) announced positive results from the RAPIDe-3 study of deucrictibant IR for treating HAE attacks, published in The Lancet. The treatment showed rapid symptom relief and resolution, with a well-tolerated safety profile. The company's NDA and MAA for deucrictibant IR are under regulatory review, with a PDUFA target date of April 23, 2027.

$PHVSMedAI 8/10

Pharvaris stock reiterated Buy at H.C. Wainwright on HAE therapy potential

H.C. Wainwright reiterated a Buy rating and $60 price target on Pharvaris (PHVS) due to positive Phase 3 data for deucrictibant, showing an 83% reduction in HAE attacks. The firm sees potential in treating acquired angioedema and expects FDA approval by April 2027. PHVS shares are down 19% since September 2026, trading at $30.49 with a $2.14B market cap. Analysts project significant upside, with price targets ranging from $41 to $79.

Pharvaris Study Shows HAE Patients Prefer Oral Prophylaxis Over Injections

Pharvaris (PHVS) published a study in Advances in Therapy showing HAE patients prefer oral prophylaxis over injections due to convenience. The analysis, based on data from 1,131 patients, found treatment satisfaction was influenced by portability, administration route, and efficacy. PHVS is developing oral bradykinin B2 receptor antagonists for HAE. The stock closed at $31.19 on October 2, 2026.

Related tickers